Statements (32)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:alternativeName |
gptkb:TKI
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:category |
targeted therapy
|
| gptkbp:contraindication |
pregnancy
|
| gptkbp:discoveredIn |
1990s
|
| gptkbp:example |
gptkb:erlotinib
gptkb:gefitinib gptkb:dasatinib gptkb:imatinib gptkb:sunitinib gptkb:lapatinib |
| https://www.w3.org/2000/01/rdf-schema#label |
Tyrosine Kinase Inhibitor
|
| gptkbp:interactsWith |
CYP3A4 inhibitors
CYP3A4 inducers |
| gptkbp:mechanismOfAction |
inhibits tyrosine kinases
|
| gptkbp:metabolism |
liver
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
diarrhea fatigue rash |
| gptkbp:target |
gptkb:BCR-ABL
gptkb:EGFR gptkb:PDGFR gptkb:VEGFR |
| gptkbp:usedFor |
gptkb:gastrointestinal_stromal_tumor
gptkb:cancer leukemia renal cell carcinoma |
| gptkbp:bfsParent |
gptkb:TKI
|
| gptkbp:bfsLayer |
8
|